Articles 08/28/2023 Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma - Cancers 2021
Articles 08/28/2023 Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma - Blood Adv. 2020
Articles 06/29/2023 IMWG consensus criteria for response and minimal residual disease assessment in Multiple Myeloma - Lancet Oncol. 2016
Articles 06/29/2023 Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma - Front Oncol. 2020
Articles 06/29/2023 Making clinical decisions based on measurable residual disease improves the outcome in Multiple Myeloma - J Hematol Oncol. 2021
Articles 06/29/2023 Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration - Clin Cancer Res. 2021
Articles 06/29/2023 Minimal Residual Disease Assessment in Multiple Myeloma Patients: Minimal Disease With Maximal Implications - Front Oncol. 2022
Articles 06/29/2023 Extramedullary disease in multiple myeloma: a systematic literature review - Blood Cancer J. 2022
Articles 06/29/2023 Modern Myeloma Therapy + Sustained Minimal Residual Disease-Negative = (Functional) Cure! - Journal of Clinical Oncology, 2022
Articles 06/08/2023 Mass spectrometry for the evaluation of monoclonal proteins in MM and related disorders - Blood Cancer J. 2021